SCYNEXIS, Inc. (SCYX)

US — Healthcare Sector
Peers: TLPH  COSM  CVKD  XCUR  KLTO  CLGN  SONN  NXL  NRXS  NRSN 

Automate Your Wheel Strategy on SCYX

With Tiblio's Option Bot, you can configure your own wheel strategy including SCYX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SCYX
  • Rev/Share 0.0588
  • Book/Share 0.7301
  • PB 0.9024
  • Debt/Equity 0.0627
  • CurrentRatio 5.7497
  • ROIC -0.8041

 

  • MktCap 27640449.0
  • FreeCF/Share -0.6732
  • PFCF -0.8229
  • PE -1.2993
  • Debt/Assets 0.0447
  • DivYield 0
  • ROE -0.5426

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
SCYX
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).

Read More
image for news SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

About SCYNEXIS, Inc. (SCYX)

  • IPO Date 2014-05-02
  • Website https://www.scynexis.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO David Gonzalez Angulo
  • Employees 28
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.